Johnson & Johnson is in talks with India's government to begin a clinical trial of its single-dose COVID-19 vaccine in the country, the company said on Friday.
The U.S. drugs and healthcare giant's vaccine is currently approved for use in the United States, the European Union and other nations including Thailand and South Africa.
The news comes as some parts of India face a shortage of vaccine supplies just as the country of 1.3 billion battles a second wave of COVID-19 infections. India's government, however, has said there is no shortage of shots.
The Indian Express newspaper reported earlier on Friday that J&J had sent a letter to India's Central Drugs Standard Control Organisation (CDSCO) saying it would "very shortly apply for permission to conduct clinical bridging trials in India".
The CDSCO did not immediately respond to Reuters request for comment.
"We are in discussions with the (government) with the objective of starting a bridging clinical study of our Janssen COVID-19 vaccine candidate in India, subject to local regulatory approvals," a local J&J representative said via email.
A bridging study tests the safety and immunogenicity of a vaccine, and India has indicated that any vaccine maker must conduct such a trial for a shot to be considered for its immunisation programme.
Separately, J&J has a deal with Indian firm Biological E Ltd to contract-manufacture its vaccine.
India currently has two approved vaccines in use, one developed by Oxford University and AstraZeneca and the other, a shot from local player Bharat Biotech.
There are other vaccine candidates in trials in India including Russia's Sputnik-V and a shot developed by Cadila Healthcare Ltd.
COVID-19 infections in India rose by a record number for a third straight day on Friday, increasing by more than 130,000, while daily deaths hit their highest in five months.
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU